KRT1
Keratin, type II cytoskeletal 1
Also known as: EHK1, K2C1_HUMAN, KRT1A
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P04264
- Gene
- KRT1
- Ensembl
- ENSG00000167768
- Chromosome
- 12
- Canonical length
- 644 aa
- Protein class
- Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins
OverviewNCBI Gene
The protein encoded by this gene is a member of the keratin gene family. The type II cytokeratins consist of basic or neutral proteins which are arranged in pairs of heterotypic keratin chains coexpressed during differentiation of simple and stratified epithelial tissues. This type II cytokeratin is specifically expressed in the spinous and granular layers of the epidermis with family member KRT10 and mutations in these genes have been associated with bullous congenital ichthyosiform erythroderma. The type II cytokeratins are clustered in a region of chromosome 12q12-q13. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
644 residues, UniProt reviewed canonical sequence.
>P04264|KRT1
1 MSRQFSSRSG YRSGGGFSSG SAGIINYQRR TTSSSTRRSG GGGGRFSSCG GGGGSFGAGG
61 GFGSRSLVNL GGSKSISISV ARGGGRGSGF GGGYGGGGFG GGGFGGGGFG GGGIGGGGFG
121 GFGSGGGGFG GGGFGGGGYG GGYGPVCPPG GIQEVTINQS LLQPLNVEID PEIQKVKSRE
181 REQIKSLNNQ FASFIDKVRF LEQQNQVLQT KWELLQQVDT STRTHNLEPY FESFINNLRR
241 RVDQLKSDQS RLDSELKNMQ DMVEDYRNKY EDEINKRTNA ENEFVTIKKD VDGAYMTKVD
301 LQAKLDNLQQ EIDFLTALYQ AELSQMQTQI SETNVILSMD NNRSLDLDSI IAEVKAQYED
361 IAQKSKAEAE SLYQSKYEEL QITAGRHGDS VRNSKIEISE LNRVIQRLRS EIDNVKKQIS
421 NLQQSISDAE QRGENALKDA KNKLNDLEDA LQQAKEDLAR LLRDYQELMN TKLALDLEIA
481 TYRTLLEGEE SRMSGECAPN VSVSVSTSHT TISGGGSRGG GGGGYGSGGS SYGSGGGSYG
541 SGGGGGGGRG SYGSGGSSYG SGGGSYGSGG GGGGHGSYGS GSSSGGYRGG SGGGGGGSSG
601 GRGSGGGSSG GSIGGRGSSS GGVKSSGGSS SVKFVSTTYS GVTRLocalizationUniProt · AlphaFold · HPA
Whether an antibody against KRT1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.62
- Highest tissue expression
- 12,288 nTPM
Expression across tissuesHPA
Tissue
- skin: 12,288 nTPM
- vagina: 1,163 nTPM
- cervix: 537 nTPM
- breast: 436 nTPM
- salivary gland: 244 nTPM
- thymus: 72 nTPM
Single-cell type
- suprabasal keratinocytes: 6,389 nCPM
- basal keratinocytes: 634 nCPM
- erythrocytes: 63 nCPM
- mast cells: 59 nCPM
- esophageal suprabasal cells: 40 nCPM
- esophageal apical cells: 15 nCPM
Immune cell
- memory CD4 T-cell: 2.3 nTPM
- memory CD8 T-cell: 0.8 nTPM
- naive CD4 T-cell: 0.7 nTPM
- total PBMC: 0.2 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
Brain region
- amygdala: 0 nTPM
- basal ganglia: 0 nTPM
- cerebellum: 0 nTPM
- cerebral cortex: 0 nTPM
- choroid plexus: 0 nTPM
- hippocampal formation: 0 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about KRT1.
Disease | AllUniProt
Conditions KRT1 is implicated in, by any mechanism.
- Epidermolytic hyperkeratosis 1 (EHK1) MIM:113800
- Ichthyosis hystrix, Curth-Macklin type (IHCM) MIM:146590
- Keratoderma, palmoplantar, non-epidermolytic (NEPPK) MIM:600962
- Ichthyosis, annular epidermolytic, 2 (AEI2) MIM:620148
- Keratoderma, palmoplantar, striate 3 (SPPK3) MIM:607654
- Palmoplantar keratoderma, epidermolytic, 2 (EPPK2) MIM:620411
Disease | GeneticClinVar
48 pathogenic / likely-pathogenic of 281 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Epidermolytic ichthyosis
- Epidermolytic hyperkeratosis 1
- Diffuse nonepidermolytic palmoplantar keratoderma
- Ichthyosis hystrix of Curth-Macklin
- Annular epidermolytic ichthyosis
Disease | ImmuneIEDB
Conditions an epitope on KRT1 was assayed in.
- multiple sclerosis B cell
- amyotrophic lateral sclerosis B cell
- neuromyelitis optica B cell
ReferencesPubMed · IEDB
Publications for KRT1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
1 publication
- Analysis of Sera of Recipients with Allograft Rejection Indicates That Keratin 1 Is the Target of Anti-Endothelial Antibodies.
2017 · J Immunol Res · RCR 0.4 · 10 citations
Reference: B cellIEDB
1 publication
- High heterogeneity of cross-reactive immunoglobulins in multiple sclerosis presumes combining of B-cell epitopes for diagnostics: a case-control study.
2024 · Front Immunol · RCR 0.9 · 5 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.4
- gnomAD pLI
- 0.74
- gnomAD missense Z
- 0.25
- DepMap mean gene effect
- -0.05
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- complement activation, lectin pathway
- cornification
- establishment of skin barrier
- fibrinolysis
- intermediate filament organization
- keratinization
- negative regulation of inflammatory response
- protein heterotetramerization
- regulation of angiogenesis
- response to oxidative stress
Molecular functions
- carbohydrate binding
- protein heterodimerization activity
- signaling receptor activity
- structural constituent of skin epidermis
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Keratin, type II
- Intermediate filament protein, conserved site
- Keratin type II head
- Intermediate filament, rod domain
- Intermediate filament protein
- Keratin type II head
- Keratin type II cytoskeletal 1, tail
- Keratin type II cytoskeletal 1 tail
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of KRT1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads KRT1 as an antibody target. Whether an autoantibody or antibody against KRT1 could matter depends on whether native KRT1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
KRT1 is annotated at the cell surface, where native KRT1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label KRT1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...